July 22nd 2024
An analysis using records from 40 million US patients highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.
Anti-VEGF Use for Diabetic Eye Diseases Increased 200% in Last Decade
January 16th 2023An analysis of a commercial claims database offers insight into the increase in vision-threatening eye disease among people with diabetes aged younger than 65 years from 2009-2018, with results also detailing trends in anti-VEGF therapy during the same period.
Diabetes Dialogue: The Prospect of a Bionic Pancreas, with Steven Russell, MD, PhD
January 14th 2023In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Steven Russell, MD, PhD, the chief medical officer of Beta Bionics, for a discussion around his journey to becoming CMO as well as a deep dive into the iLet Bionic Pancreas and its potential in diabetes management.
FDA Updates Label for Oral Semaglutide, Making Agent a First-Line Therapy in Type 2 Diabetes
January 13th 2023Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.
Rates of Type 1, Type 2 Diabetes Expected to Balloon in US by 2060
January 12th 2023Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.
Presence of Diabetes Linked to Greater Likelihood of Frozen Shoulder
January 10th 2023Eight studies provided evidence to suggest the relationship between diabetes and the onset of frozen shoulder, but more high-quality cohort studies may be necessary to better understand the nature of the relationship.
SGLT2 Inhibitors Can Aid Weight Loss, Reduce Fat Mass in People with Type 2 Diabetes
January 7th 2023Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.
SGLT2 Inhibitors Can Reduce Cardiometabolic Risk in People with Diabetes Using Metformin
January 6th 2023Using data from more than 55,000 people with diabetes using metformin is providing new insight into the apparent reductions in risk of negative cardiovascular and renal outcomes as well as all-cause mortality with use of SGLT2 inhibitors.
Optimal Glycemic Control Could Slow Biological Aging in Adults with Type 2 Diabetes
January 4th 2023Exploratory analyses of data from the Look AHEAD trial suggest maintaining an HbA1c level of 7% or less was associated with smaller increases in frailty index over the 8-year study period when compared to their counterparts with an HbA1c level of 8% or greater.
Top New Cardiometabolic Health Guidelines/Recommendations in 2022
December 28th 2022Our recap of new guidelines and recommendations related to diabetes management from 2022 includes the 2023 Standards of Care, USPSTF recommendation on type 2 diabetes screenings in adolescents, recommendations for pharmacologic management of obesity, new bariatric surgery guidance, and a consensus report on use of automated insulin delivery.
Diabetes Dialogue: 2022 Year in Review
December 27th 2022To commemorate the inaugural year and the success of Diabetes Dialogue in 2022, our editorial team has compiled a list of the 5 most popular episodes from the past year. Further in this article, we offer readers a look into each of our hosts top picks for episodes during 2022.